Ceapro Posts Highest Quarterly Revenues Reported in Company's History Expected Commencement of Clinical Program With Avenanthramides as Anti-Inflammatory Compound Before Year End Pilot Clinical Study to Develop Beta Glucan as a Cholesterol Reducer on Track to Initiate in Q3 2016

 

EDMONTON, ALBERTA--(May 18, 2016) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the three-months ended March 31, 2016 and provided a business update.

 

Financial Highlights for the First Quarter 2016

Best first quarter performance with revenues reaching historical highs;

Total sales of $4,064,000 for the quarter ended March 31, 2016 compared to $1,714,000 in 2015, an increase of 137% quarter-over-quarter revenue performance;

Company fortifies IP position ahead of New Drug Application to FDA

 

TEL-AVIV, Israel, May 12, 2016 -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, announced today the U.S. Patent and Trademark Office has issued a Notice of Allowance to the Company for claims covering important treatment methodologies, which form the basis of its lead drug candidate, KIT-302, and that ameliorate celecoxib-induced elevation of blood pressure, which can result from prolonged use of the drug. 

 

A combination drug, KIT-302 simultaneously treats pain caused by osteoarthritis and treats hypertension, which is a common side effect of stand-alone drugs that treat osteoarthritis pain.   KIT-302 is comprised of two FDA approved drugs, celecoxib (Celebrex®) for the treatment of pain caused by osteoarthritis and amlodipine besylate, a drug designed to treat hypertension. The Company plans to file a New Drug Application for KIT-302 at the end of 2016.

NEWARK, Calif., May 10, 2016  -- StemCells, Inc. (STEM), a leading stem cell company developing novel cell-based therapeutics for the treatment of serious central nervous system diseases, today announced that it will be presenting top line 12-month data from Cohort I of its Pathway™ Study later this month as part of the Company’s first quarter 2016 analyst call. The Company is planning to then release detailed final data on Cohort I at a scientific venue in June.

 

The Pathway Study is a single blind, randomized, controlled clinical trial investigating the use of the Company’s proprietary HuCNS-SC® human neural stem cells for the treatment of chronic spinal cord injuries. The goal of the Pathway Study is to demonstrate improved upper body motor function and fine motor skills.

- Company Announces Exclusive License Agreement with Vifor Pharma to Commercialize Orally Administered Complement 5a Receptor Inhibitor CCX168 in Europe and Certain Other Markets; Agreement Includes $85 Million Upfront, Comprising $60 Million in Cash in Addition to $25 Million Equity Investment -

- Patients Complete Treatment Period in AAV Phase II CLASSIC Trial of CCX168; Top Line Data Expected June 2016 -

- Expecting Data from Pancreatic Cancer Trial of CCX872: Initial Objective Response Rates Mid-year; Initial Progression Free Survival Results in the Second Half of 2016 -

- Conference Call Today at 8:30 a.m. Eastern Time -

 

MOUNTAIN VIEW, Calif., May 10, 2016  -- ChemoCentryx, Inc., (CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today reported financial results for the first quarter ended March 31, 2016 and provided an update on the Company’s corporate and clinical development activities.